#USA #Boston #Morphic Medical #Joe Virgilio #Mike Gutteridge

Morphic Medical Announces Leadership Transition

Boston, August 5, 2025 - Morphic Medical, a pioneering medical technology company specializing in minimally invasive treatments for obesity and cardiometabolic disorders, has declared a significant leadership change aimed at fostering continued growth and evolution within the organization.

After five dedicated years at the helm, Joe Virgilio will step down as Chief Executive Officer. During his tenure, Morphic Medical achieved several crucial milestones in product development, manufacturing enhancements, and organizational growth. Notably, he was instrumental in overseeing regulatory initiatives that led to the approval of RESET® under the European Union's Medical Device Regulation (MDR) earlier this month.

The board of directors is pleased to announce that Mike Gutteridge will be appointed as the new CEO. Mike brings extensive experience from the field of bariatric endoscopy, having previously served as Vice President of Therapy Development and Commercial Operations at Morphic, where he played a key role in crafting the marketing strategy for RESET®.

Mark Lerdal, the Chair of the Board, stated, "Joe has been essential in transforming Morphic Medical into what it is today. We are grateful for his vision, leadership, and commitment to innovation and patient care. At the same time, we are excited to welcome Mike, who shares our values and comes with a successful track record in international marketing, as we start our next phase of growth."

Reflecting on his departure, Joe Virgilio expressed, "It has been a privilege to lead Morphic Medical for the past five years. I am proud of the accomplishments of our outstanding team and have confidence in the future of the company under Mike’s leadership. I remain committed to the mission and look forward to supporting Mike and the board during this transition into an exciting new chapter."

Mike Gutteridge added, "I am honored to take over as CEO of Morphic Medical, succeeding Joe Virgilio, and am deeply thankful for his continued support as I embark on this new journey. With over 30 years of experience in the medical technology field, encompassing clinical innovation, commercial strategy, market development, and reimbursement, I am thrilled at the opportunity to lead Morphic into its next phase which focuses on global markets, accelerated commercialization, and deepening our commitment to enhancing patients' lives through effective and lasting therapies.

As CEO, I will build on Morphic’s pioneering work in gastrointestinal metabolic health and will continue to foster a culture of agility, purpose, and collaboration within our exceptional team and with our growing network of physicians, researchers, and investors. Together, we will ensure Morphic’s technology reaches those who need it most while creating sustainable value through responsible growth.

This is an exciting moment for our company, and I take pride in contributing to shaping what is to come."

The leadership transition will be managed diligently over the coming months to ensure continuity across operations, stakeholders, and partnerships.

About Morphic Medical

Morphic Medical is the developer of RESET, an endoscopic therapy offering a non-surgical alternative for treating severe obesity or obesity with concurrent cardiometabolic risk factors, such as type 2 diabetes or dyslipidemia. RESET is not approved for sale in the United States and its use is limited by federal law to investigational purposes only. Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts. For more information, visit morphicmedical.com or follow us on Twitter and LinkedIn.

Contact for Media Inquiries:
Morphic Medical Investor Relations
Email: [email protected]
Phone: +1 (781) 357-3296